Canary Capital has officially filed for a Staked Injective (INJ) exchange-traded fund (ETF) trust in Delaware. The filing outlines a vehicle designed to hold INJ tokens while simultaneously participating in Injective’s staking contracts.
Beyond simply tracking the Injective token price, the proposed ETF aims to pass staking rewards generated to investors, presenting a dual-benefit model that combines potential asset appreciation with yield.
The announcement triggered an immediate market response, with INJ’s price rising approximately 5% as investor sentiment reacted positively to the potential for regulated altcoin exposure and enhanced liquidity via a traditional finance product.
This move builds upon Canary Capital’s portfolio of previous ETF filings targeting assets like TRON, Sui, and XRP, signaling a continued strategy to bridge specific altcoins into regulated investment vehicles.
The pending approval of such an ETF by regulators carries significant weight. If successful, it could mark a pivotal step forward for altcoin-based staking ETFs, echoing the market impact previously seen with the introduction of spot Bitcoin ETFs.